ANR and Grants
Nano-H has collaborated with numerous companies and academic laboratories on collaborative projects, participating in 17 ANR, European, or other projects as a co-developer or contractor.
Currently, Nano-H is actively engaged in three innovative projects: I-DECoRP, focusing on the development of a radioprotective drug for large-scale nuclear risk scenarios; IRHydroBRAIN, aimed at advancing glioblastoma treatment with radiolabeled hydrogels; and IMITATE, which develops cutting-edge in-vitro models to enhance nanoparticle transport and radiotherapy efficacy. These projects reflect Nano-H’s commitment to pioneering research and technological advancement in healthcare.
I Decorp, 2025
Nano-H is proud to be part of the consortium working on the I-DECoRP project, an I-DEMO initiative funded under the France 2030 program. The project addresses a critical unmet need in radioprotection: developing a safe, effective, and easy-to-administer radioprotective drug capable of acting across a broad spectrum of radionuclides. Unlike existing solutions tailored for specific radionuclides, I-DECoRP aims to provide a strategic response to large-scale nuclear risks and diverse contamination scenarios.
The project’s first goal is to bring a tablet-based formulation to clinical trials, offering a simple yet robust means of protecting populations from contamination by ingestion. Future developments aim to expand the concept to address contamination by inhalation and skin exposure. This innovative approach is built on MexBrain’s ultrachelating biopolymer technology, developed in collaboration with academic, hospital, and industrial partners, including Nano-H, IRSN, IGR, and UCBL.
Beyond nuclear radioprotection, the technology shows promise for additional applications, such as protecting healthy tissues during radiotherapy and mitigating exposure to heavy metals like cadmium and lead, particularly in patients with comorbidities such as kidney insufficiencies. Together, the consortium is driving innovation to address contemporary and future challenges in radioprotection and beyond.
IRHydroBRAIN, 2025
Nano-H is also actively contributing to the recently accepted IRHydroBRAIN project, a collaborative research initiative funded under the PRCE program. This project focuses on developing a radiolabeled chitosan hydrogel for internal radiation therapy of glioblastoma, one of the most aggressive forms of brain cancer. By leveraging its expertise in polysaccharide chelation.
Nano-H plays a key role in optimizing the hydrogel’s formulation for use with isotopes such as Yttrium-90 or Lutetium-177. The project aims to enhance local tumor control and reduce recurrence rates, integrating in vitro 3D tumor models, in vivo studies, and dosimetry analyses to validate treatment parameters. This ambitious initiative has the potential to lead to clinical trials, paving the way for improved therapeutic strategies in oncology.
IMITATE, 2024
Nano-H is actively contributing to the IMITATE project, an innovative research initiative funded under the PRCE program. This project aims to develop an integrated 3D in-vitro platform to model and predict nanoparticle transport and radiotherapy efficacy in a physiological tumor environment. By leveraging hydrogel-based microsystems, IMITATE replicates the complex mechanical, hypoxic, and metabolic conditions found in tumors.
Nano-H plays a key role in synthesizing nanoparticles and polymer probes to analyze their transport and therapeutic effects. This approach enables a deeper understanding of nanoparticle behavior, improving the predictive accuracy for cancer therapies and optimizing future clinical applications.